Serum Autoantibodies against STIP1 as a Potential Biomarker in the Diagnosis of Esophageal Squamous Cell Carcinoma

Table 4

Relationship between positive rate of the STIP1 autoantibodies and clinical data in ESCC patients from the training cohort.

	N	Positive (%, 95% CI)	P
Age
≥58	84	40 (47.6, 36.7–58.7)	0.106
<58	64	22 (34.4, 23.3–47.4)
Gender
Male	114	49 (43.0, 33.8–52.6)	0.622
Female	34	13 (38.2, 22.7–56.4)
Smoke
Yes	106	45 (42.5, 33.0–52.4)	0.826
No	42	17 (40.5, 26.0–56.7)
Site of tumor
Upper thorax	15	7 (46.7, 22.3–72.6)	0.880
Middle thorax	101	41 (40.6, 31.1–50.8)
Low thorax	32	14 (43.8, 26.8–62.1)
Size of tumor
<5 cm	71	32 (45.1, 33.4–57.3)	0.452
≥5 cm	77	30 (39.0, 28.3–50.8)
Depth of tumor invasion
T1 + T2	30	9 (30.0, 15.4–49.6)	0.133
T3 + T4	115	52 (45.2, 36.0–54.8)
Regional lymph nodes
N0	77	30 (39.0, 28.3–50.8)	0.452
N1 + N2 + N3	71	32 (45.1, 33.4–57.3)
Histological grade
G1	50	18 (36.0, 23.3–50.9)	0.440
G2	84	39 (46.4, 35.6–57.6)
G3	14	5 (35.7, 14.0–64.4)
TNM stage
Early stage (0 + I + IIA)	42	15 (35.7, 22.0–52.0)	0.338
Advanced stage (IIB + III + IV)	106	47 (44.3, 34.8–54.3)

ESCC: esophageal squamous cell carcinoma; CI: exact confidence interval. Statistical significance was determined using the chi-square test.